108 related articles for article (PubMed ID: 10409883)
1. [New antiplatelet agents].
Beer JH
Praxis (Bern 1994); 1999 May; 88(19):853-60. PubMed ID: 10409883
[TBL] [Abstract][Full Text] [Related]
2. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
Serebruany VL; Malinin AI; Jerome SD; Lowry DR; Morgan AW; Sane DC; Tanguay JF; Steinhubl SR; O'connor CM
Am Heart J; 2003 Oct; 146(4):713-20. PubMed ID: 14564328
[TBL] [Abstract][Full Text] [Related]
3. Antiplatelet agents and arterial thrombosis.
Billett HH
Cardiol Clin; 2008 May; 26(2):189-201, vi. PubMed ID: 18406994
[TBL] [Abstract][Full Text] [Related]
4. Antithrombotic drugs in vascular medicine: a historical perspective.
Schrör K
Semin Vasc Med; 2003 May; 3(2):97-105. PubMed ID: 15199472
[TBL] [Abstract][Full Text] [Related]
5. Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination.
Cooke GE; Liu-Stratton Y; Ferketich AK; Moeschberger ML; Frid DJ; Magorien RD; Bray PF; Binkley PF; Goldschmidt-Clermont PJ
J Am Coll Cardiol; 2006 Feb; 47(3):541-6. PubMed ID: 16458133
[TBL] [Abstract][Full Text] [Related]
6. The expanding role of antiplatelet agents in coronary artery disease. A current review of aspirin, glycoprotein IIb/IIIa inhibitors, and the thienopyridines.
Hostetter JC; Bhatt DL
Minerva Cardioangiol; 2003 Oct; 51(5):531-46. PubMed ID: 14551522
[TBL] [Abstract][Full Text] [Related]
7. Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond.
Konstantopoulos K; Mousa SA
Curr Opin Investig Drugs; 2001 Aug; 2(8):1086-92. PubMed ID: 11892918
[TBL] [Abstract][Full Text] [Related]
8. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?
Bliden KP; DiChiara J; Tantry US; Bassi AK; Chaganti SK; Gurbel PA
J Am Coll Cardiol; 2007 Feb; 49(6):657-66. PubMed ID: 17291930
[TBL] [Abstract][Full Text] [Related]
9. [Platelet aggregation inhibitors in diabetes mellitus].
Abrahamian H
Acta Med Austriaca; 1999; 26(5):137-41. PubMed ID: 11512189
[TBL] [Abstract][Full Text] [Related]
10. Current antiplatelet therapies: benefits and limitations.
Angiolillo DJ; Guzman LA; Bass TA
Am Heart J; 2008 Aug; 156(2 Suppl):S3-9. PubMed ID: 18657680
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ;
Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312
[TBL] [Abstract][Full Text] [Related]
12. Does clopidogrel increase the degree of platelet inhibition when a platelet glycoprotein IIb/IIIa inhibitor has been given? Insights from an optical platelet aggregometry study.
Talreja D; Lubbe D; Orford JL; Lennon R; DiBattiste PM; Berger PB
J Thromb Thrombolysis; 2004 Aug; 18(1):25-30. PubMed ID: 15744550
[TBL] [Abstract][Full Text] [Related]
13. Variability in platelet response to the antiplatelet agents aspirin and clopidogrel: mechanisms, measurement, and clinical relevance.
Jennings LK
Crit Pathw Cardiol; 2009 Mar; 8(1):20-8. PubMed ID: 19258834
[TBL] [Abstract][Full Text] [Related]
14. An overview of commonly used antiplatelet agents.
Bungard TJ
Can J Cardiovasc Nurs; 1998; 9(3):38-46. PubMed ID: 10335141
[TBL] [Abstract][Full Text] [Related]
15. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Macaya C
Am J Cardiol; 2006 Jan; 97(1):38-43. PubMed ID: 16377281
[TBL] [Abstract][Full Text] [Related]
16. Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
Ferguson JJ; Wilson JM; Diez J
Minerva Cardioangiol; 2007 Oct; 55(5):529-56. PubMed ID: 17912162
[TBL] [Abstract][Full Text] [Related]
17. Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study with whole-blood aggregometry.
Bauriedel G; Skowasch D; Schneider M; Andrié R; Jabs A; Lüderitz B
Am Heart J; 2003 Feb; 145(2):343-8. PubMed ID: 12595854
[TBL] [Abstract][Full Text] [Related]
18. Influence of different antiplatelet treatment regimens for primary percutaneous coronary intervention on all-cause mortality.
Witkowski A; Maciejewski P; Wasek W; Malek LA; Niewada M; Kaminski B; Drzewiecki J; Kosmider M; Kubica J; Ruzyllo W; Peruga JZ; Dudek D; Opolski G; Dobrzycki S; Gil RJ;
Eur Heart J; 2009 Jul; 30(14):1736-43. PubMed ID: 19376786
[TBL] [Abstract][Full Text] [Related]
19. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Patrono C; Coller B; FitzGerald GA; Hirsh J; Roth G
Chest; 2004 Sep; 126(3 Suppl):234S-264S. PubMed ID: 15383474
[TBL] [Abstract][Full Text] [Related]
20. Platelet glycoprotein IIb/IIIa inhibitors.
Rosove MH
Best Pract Res Clin Haematol; 2004 Mar; 17(1):65-76. PubMed ID: 15171958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
